About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(Myhca-cre)1Abel
transgene insertion 1, E Dale Abel
MGI:2182091
Summary 10 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Tmsb4xtm1.2Chen/Y
Tg(Myhca-cre)1Abel/0
involves: 129S1/Sv * 129X1/SvJ * Black Swiss MGI:5428019
cn2
Bag3tm1c(EUCOMM)Hmgu/Bag3tm1.1Chen
Tg(Myhca-cre)1Abel/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * FVB/N MGI:6107910
cn3
Slc2a4tm1Abel/Slc2a4tm1Abel
Tg(Myhca-cre)1Abel/?
involves: 129S4/SvJae * C57BL/6 * FVB MGI:3629925
cn4
Slc2a4tm1Abel/Slc2a4tm1Abel
Tg(Myhca-cre)1Abel/?
involves: 129S4/SvJae * FVB MGI:3029363
cn5
Insrtm1Khn/Insrtm1Khn
Tg(Myhca-cre)1Abel/0
involves: 129S4/SvJae * FVB MGI:3620045
cn6
Dnaja3tm1.1Jdl/Dnaja3tm1.1Jdl
Tg(Myhca-cre)1Abel/0
involves: 129X1/SvJ * C57BL/6J * FVB MGI:3665423
cn7
Bag3tm1c(EUCOMM)Hmgu/Bag3tm1c(EUCOMM)Hmgu
Tg(CAG-EGFP/Map1lc3b)53Nmz/0
Tg(Myhca-cre)1Abel/0
involves: C57BL/6 * C57BL/6N * C57BL/6NCrlj * DBA/2 * FVB/N MGI:6107905
cn8
Bag3tm1c(EUCOMM)Hmgu/Bag3tm1c(EUCOMM)Hmgu
Tg(Myhca-cre)1Abel/0
involves: C57BL/6N * FVB/N MGI:6107901
cn9
Dot1ltm1Tche/Dot1ltm1.1Tche
Tg(Myhca-cre)1Abel/0
Not Specified MGI:5424158
cn10
Mapk7tm1Jdl/Mapk7tm1Jdl
Tg(Myhca-cre)1Abel/0
Not Specified MGI:3042043


Genotype
MGI:5428019
cn1
Allelic
Composition
Tmsb4xtm1.2Chen/Y
Tg(Myhca-cre)1Abel/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * Black Swiss
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Myhca-cre)1Abel mutation (0 available)
Tmsb4xtm1.2Chen mutation (0 available); any Tmsb4x mutation (11 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• mutant mice are viable to adulthood




Genotype
MGI:6107910
cn2
Allelic
Composition
Bag3tm1c(EUCOMM)Hmgu/Bag3tm1.1Chen
Tg(Myhca-cre)1Abel/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * FVB/N
Cell Lines HEPD0556_7_B06
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bag3tm1.1Chen mutation (0 available); any Bag3 mutation (31 available)
Bag3tm1c(EUCOMM)Hmgu mutation (1 available); any Bag3 mutation (31 available)
Tg(Myhca-cre)1Abel mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Cardiac enlargement in Bag3tm1c(EUCOMM)Hmgu/Bag3tm1.1Chen Tg(Myhca-cre)1Abel/0 mice at 6 months of age

cardiovascular system
• cardiac enlargement
• heart weight to body weight and heart weight to tibia length ratios are increased at 5 months of age
• diminished systolic function
• diminished systolic function with mice showing reduced fractional shortening, increased left ventricle internal diameter at end diastole and increased left ventricle internal diameter at end systole

homeostasis/metabolism
• hearts exhibit impaired autophagic flux

cellular
• hearts exhibit impaired autophagic flux

muscle
• diminished systolic function

growth/size/body
• cardiac enlargement
• heart weight to body weight and heart weight to tibia length ratios are increased at 5 months of age

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
dilated cardiomyopathy 1HH DOID:0110448 OMIM:613881
J:246352




Genotype
MGI:3629925
cn3
Allelic
Composition
Slc2a4tm1Abel/Slc2a4tm1Abel
Tg(Myhca-cre)1Abel/?
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc2a4tm1Abel mutation (0 available); any Slc2a4 mutation (35 available)
Tg(Myhca-cre)1Abel mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• during normal perfusion, glycogen content is 54% higher in fed mutants than in fed wild-type, however no difference in myocardial glycogen in fasted mice
• during normal perfusion, hearts from fed homozygotes show higher concentrations of phosphocreatine
• during ischemia, hearts from fasted homozygotes exhibit depressed glucose utilization
• during normal perfusion, hearts from fed homozygotes show a 3-fold increase in glucose uptake, while fasted hearts show identical levels of basal glucose uptake as wild-type
• fasting results in a 20% decrease in left ventricular systolic pressure, however heart rates and coronary flow rates are unaffected by fasting
• hearts exhibit delayed recovery after low-flow ischemia
• hearts of fasted mutants exhibit decreased lactate production (75%) indicating depressed glucose utilization during ischemia and develop irreversible systolic and diastolic dysfunction as indicated by an increase in left ventricular end-diastolic pressure that remains elevated on reperfusion and a left ventricular developed pressure that does not recovery fully, as well as impaired ability to generate ATP during ischemia (accelerated depletion of ATP and decreased levels of ATP recovery on reperfusion)
• hearts of fed mutants exhibit normal left ventricular pressure during ischemia, however recovery of the left ventricular developed pressure is delayed during reperfusion and hearts exhibit a decrease (28%) in lactate production during ischemia

homeostasis/metabolism
• during normal perfusion, glycogen content is 54% higher in fed mutants than in fed wild-type, however no difference in myocardial glycogen in fasted mice
• hearts exhibit delayed recovery after low-flow ischemia
• hearts of fasted mutants exhibit decreased lactate production (75%) indicating depressed glucose utilization during ischemia and develop irreversible systolic and diastolic dysfunction as indicated by an increase in left ventricular end-diastolic pressure that remains elevated on reperfusion and a left ventricular developed pressure that does not recovery fully, as well as impaired ability to generate ATP during ischemia (accelerated depletion of ATP and decreased levels of ATP recovery on reperfusion)
• hearts of fed mutants exhibit normal left ventricular pressure during ischemia, however recovery of the left ventricular developed pressure is delayed during reperfusion and hearts exhibit a decrease (28%) in lactate production during ischemia

muscle
• during normal perfusion, glycogen content is 54% higher in fed mutants than in fed wild-type, however no difference in myocardial glycogen in fasted mice
• during ischemia, hearts from fasted homozygotes exhibit depressed glucose utilization
• during normal perfusion, hearts from fed homozygotes show a 3-fold increase in glucose uptake, while fasted hearts show identical levels of basal glucose uptake as wild-type

cellular
• during ischemia, hearts from fasted homozygotes exhibit depressed glucose utilization
• during normal perfusion, hearts from fed homozygotes show a 3-fold increase in glucose uptake, while fasted hearts show identical levels of basal glucose uptake as wild-type




Genotype
MGI:3029363
cn4
Allelic
Composition
Slc2a4tm1Abel/Slc2a4tm1Abel
Tg(Myhca-cre)1Abel/?
Genetic
Background
involves: 129S4/SvJae * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc2a4tm1Abel mutation (0 available); any Slc2a4 mutation (35 available)
Tg(Myhca-cre)1Abel mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• cross sectional area of myocytes was greater
• gross morphology of the heart was normal however
• both heart weight and heart wt/body wt ratio were significantly increased
• develop cardiac hypertrophy, however contractile function is preserved
• increased ANP production
• insulin mediated glucose uptake was abolished in the heart

growth/size/body
• both heart weight and heart wt/body wt ratio were significantly increased
• develop cardiac hypertrophy, however contractile function is preserved
• growth was normal up to about 6 months
• body weight in older males was reduced relative to wild-type males

homeostasis/metabolism
• basal glucose uptake about 4X normal in males and 2X normal in females
• insulin mediated glucose uptake was abolished in the heart
• glucose tolerance was normal until about 30 weeks of age when mild impairment was seen in females

muscle
• cross sectional area of myocytes was greater
• gross morphology of the heart was normal however
• insulin mediated glucose uptake was abolished in the heart

nervous system
• increased BNP production

cellular
• insulin mediated glucose uptake was abolished in the heart




Genotype
MGI:3620045
cn5
Allelic
Composition
Insrtm1Khn/Insrtm1Khn
Tg(Myhca-cre)1Abel/0
Genetic
Background
involves: 129S4/SvJae * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Insrtm1Khn mutation (1 available); any Insr mutation (94 available)
Tg(Myhca-cre)1Abel mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• hearts have 2.3 times the glycogen content of wild-type and insulin administration reduces levels to those seen in wild-type
• decrease in cardiomyocyte size, with myocyte length and width reduced by 6 and 9%, respectively
• exhibit a persistence of the fetal pattern of cardiac metabolism, indicating that the metabolic switch from predominant glucose metabolism, as seen in neonatal hearts, to fatty acid metabolism that characterizes the adult heart, is defective
• 20-30% reduction in size due to reduced cardiomyocyte size
• decrease in LV posterior wall thickness
• cardiac power, determined by cardiac output and developed pressure, is modestly reduced
• cardiac output is about 15% lower than in wild-type
• physiological concentrations of insulin do not cause an increase in myocyte glucose uptake as in wild-type
• decrease in basal glucose uptake in isolated cardiac myocytes
• 68% increase in the basal rate of cardiac glucose uptake in intact hearts in vivo and in isolated working hearts
• exhibit an increase in left ventricular systolic dimension without any change in diastolic dimension, a 29% reduction in fractional shortening, and 12% reduction in ejection fraction

homeostasis/metabolism
• basal rates of glycolysis in hearts are significantly higher than in wild-type, and do not increase further upon insulin treatment
• basal rates of glucose oxidation in isolated hearts are 30% lower than in wild-type, however insulin increases oxidation rates to a similar rate seen in insulin-treated wild-type hearts
• hearts have 2.3 times the glycogen content of wild-type and insulin administration reduces levels to those seen in wild-type
• basal rates of palmitate oxidation in isolated hearts are 34% lower than in wild-type and do not change further after insulin stimulation

muscle
• hearts have 2.3 times the glycogen content of wild-type and insulin administration reduces levels to those seen in wild-type
• decrease in cardiomyocyte size, with myocyte length and width reduced by 6 and 9%, respectively
• physiological concentrations of insulin do not cause an increase in myocyte glucose uptake as in wild-type
• decrease in basal glucose uptake in isolated cardiac myocytes
• 68% increase in the basal rate of cardiac glucose uptake in intact hearts in vivo and in isolated working hearts
• exhibit an increase in left ventricular systolic dimension without any change in diastolic dimension, a 29% reduction in fractional shortening, and 12% reduction in ejection fraction

cellular
• physiological concentrations of insulin do not cause an increase in myocyte glucose uptake as in wild-type
• decrease in basal glucose uptake in isolated cardiac myocytes
• 68% increase in the basal rate of cardiac glucose uptake in intact hearts in vivo and in isolated working hearts




Genotype
MGI:3665423
cn6
Allelic
Composition
Dnaja3tm1.1Jdl/Dnaja3tm1.1Jdl
Tg(Myhca-cre)1Abel/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6J * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dnaja3tm1.1Jdl mutation (0 available); any Dnaja3 mutation (43 available)
Tg(Myhca-cre)1Abel mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• only ~5% of mutant mice are obtained at 2 weeks of age (i.e. ~20% of expected Mendelian ratio), with no differences in survival ratio after backcrossing to C57BL/6J or FVB for two generations
• all surviving mutants die before the age of 10 weeks
• most mutant embryos die between E10.5 and E13.5

cardiovascular system
• at 4 weeks of age, mutant cardiomyocytes exhibit swollen mitochondria with electron-dense bodies and disarrayed sarcomeres
• mitochondrial abnormalities precede any other subcellular changes in mutant hearts
• mutant cardiomyocytes show decreased copy number of mitochondrial DNA
• at E10.5, mutant embryos exhibit impaired trabecular formation
• at 4 weeks of age, surviving mutants have an enlarged heart
• at E10.5, mutant embryos display pericardial effusion
• at 4 weeks, mutant hearts exhibit mild interstitial fibrosis
• at 4 weeks of age, mutants display dilated ventricular chambers, impaired contractility and pressure volume loops suggestive of dilated cardiomyopathy
• at 4 weeks of age, mutants display impaired ventricular contractility
• at 4 weeks of age, mutants exhibit a mosaic pattern of cardiomyocyte degeneration, with a significant increase in cardiomyocyte apoptosis
• at 4 weeks of age, surviving mutants exhibit features of congestive heart failure, i.e. enlarged hearts, pleural effusions and edematous connective tissues

embryo
• most mutant embryos are growth retarded, with their heart size remaining similar to that of E10.5 control embryos

cellular
• mutant cardiomyocytes show decreased copy number of mitochondrial DNA
• at 4 weeks, mutant hearts exhibit mild interstitial fibrosis
• at 4 weeks of age, mutants exhibit a mosaic pattern of cardiomyocyte degeneration, with a significant increase in cardiomyocyte apoptosis
• at 4 weeks of age, mutant cardiomyocytes exhibit swollen mitochondria with electron-dense bodies
• mutant cardiomyocytes show progressive respiratory chain deficiency
• as expected, all mitochondrial respiratory chain functions remain at normal levels in skeletal muscle

growth/size/body
• at 4 weeks of age, surviving mutants have an enlarged heart
• most mutant embryos are growth retarded, with their heart size remaining similar to that of E10.5 control embryos

behavior/neurological
• at 3 weeks of age, mutant survivors exhibit reduced locomotor activity

muscle
• at 4 weeks of age, mutant cardiomyocytes exhibit swollen mitochondria with electron-dense bodies and disarrayed sarcomeres
• mitochondrial abnormalities precede any other subcellular changes in mutant hearts
• mutant cardiomyocytes show decreased copy number of mitochondrial DNA
• at E10.5, mutant embryos exhibit impaired trabecular formation
• at 4 weeks of age, mutants display dilated ventricular chambers, impaired contractility and pressure volume loops suggestive of dilated cardiomyopathy
• at 4 weeks of age, mutants display impaired ventricular contractility
• at 4 weeks of age, mutants exhibit a mosaic pattern of cardiomyocyte degeneration, with a significant increase in cardiomyocyte apoptosis
• at 4 weeks of age, mutant cardiomyocytes display disarrayed sarcomeres

homeostasis/metabolism
• at E10.5, mutant embryos display pericardial effusion




Genotype
MGI:6107905
cn7
Allelic
Composition
Bag3tm1c(EUCOMM)Hmgu/Bag3tm1c(EUCOMM)Hmgu
Tg(CAG-EGFP/Map1lc3b)53Nmz/0
Tg(Myhca-cre)1Abel/0
Genetic
Background
involves: C57BL/6 * C57BL/6N * C57BL/6NCrlj * DBA/2 * FVB/N
Cell Lines HEPD0556_7_B06
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bag3tm1c(EUCOMM)Hmgu mutation (1 available); any Bag3 mutation (31 available)
Tg(CAG-EGFP/Map1lc3b)53Nmz mutation (5 available)
Tg(Myhca-cre)1Abel mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• after 18 hours of starvation, mice exhibit a reduction in LC3-GFP accumulation in the myocardium, indicating suppressed autophagic flux in hearts

homeostasis/metabolism
• after 18 hours of starvation, mice exhibit a reduction in LC3-GFP accumulation in the myocardium, indicating suppressed autophagic flux in hearts




Genotype
MGI:6107901
cn8
Allelic
Composition
Bag3tm1c(EUCOMM)Hmgu/Bag3tm1c(EUCOMM)Hmgu
Tg(Myhca-cre)1Abel/0
Genetic
Background
involves: C57BL/6N * FVB/N
Cell Lines HEPD0556_7_B06
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bag3tm1c(EUCOMM)Hmgu mutation (1 available); any Bag3 mutation (31 available)
Tg(Myhca-cre)1Abel mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Dilated cardiomyopathy in Bag3tm1c(EUCOMM)Hmgu/Bag3tm1c(EUCOMM)Hmgu Tg(Myhca-cre)1Abel/0 mice

homeostasis/metabolism
• neonatal cardiomyocytes exhibit suppression of autophagosome formation following bafilomycin-A1 and chloroquine treatment
• neonatal cardiomyocytes exhibit suppression of autophagosome formation following bafilomycin-A1 and chloroquine treatment indicating impaired autophagy

mortality/aging
• mice are susceptible to premature death, with only 9% of mice surviving past 20 months of age

cardiovascular system
• cardiac enlargement in 6 month old mice
• heart weight to body weight and heart weight to tibia length ratios are increased at 4 months of age
• severe fibrosis in surviving 6 month old mice
• peak rate of pressure rise and peak rate of pressure decline are reduced as early as 10 weeks of age, indicating early impairment of cardiac contractile function
• single myocyte contraction induced by field stimulation is reduced
• however, the profiles of induced calcium transients, including amplitude and tau, are not affected
• neonatal cardiomyocytes exhibit suppression of autophagosome formation following bafilomycin-A1 and chloroquine treatment indicating impaired autophagy
• echocardiography shows an age-dependent decrease in left ventricular systolic function, and left ventricle chamber dilation as evidenced by an increase in end-diastolic left ventricle internal diameter and end-systolic left ventricle internal diameter
• single myocyte contraction induced by field stimulation is reduced

cellular
• neonatal cardiomyocytes exhibit suppression of autophagosome formation following bafilomycin-A1 and chloroquine treatment
• neonatal cardiomyocytes exhibit suppression of autophagosome formation following bafilomycin-A1 and chloroquine treatment indicating impaired autophagy

muscle
• peak rate of pressure rise and peak rate of pressure decline are reduced as early as 10 weeks of age, indicating early impairment of cardiac contractile function
• single myocyte contraction induced by field stimulation is reduced
• however, the profiles of induced calcium transients, including amplitude and tau, are not affected

growth/size/body
• cardiac enlargement in 6 month old mice
• heart weight to body weight and heart weight to tibia length ratios are increased at 4 months of age

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
dilated cardiomyopathy 1HH DOID:0110448 OMIM:613881
J:246352




Genotype
MGI:5424158
cn9
Allelic
Composition
Dot1ltm1Tche/Dot1ltm1.1Tche
Tg(Myhca-cre)1Abel/0
Genetic
Background
Not Specified
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dot1ltm1.1Tche mutation (0 available); any Dot1l mutation (69 available)
Dot1ltm1Tche mutation (0 available); any Dot1l mutation (69 available)
Tg(Myhca-cre)1Abel mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice surviving the early postnatal period died by 6 mo of age
• sudden death was observed in 50% of the mutant mice within 2 wk after birth

cardiovascular system
• gross changes in heart morphology (such as deviation from an elliptical shape to a more spherical one and increased heart mass) are observed
• RT-qPCR demonstrated that expression of the fetal genes Myh7, Acta1, Nppa, and Nppb is up-regulated in mutant hearts, and adult gene Myh6 is down-regulated indicating reactivation of a fetal gene expression program
• heart to body weight ratios are increased compared with that of littermate controls; body weight is not significantly altered between controls and mutant mice
• conscious ECHOs performed on P10 pups demonstrate that mutant mice have increased left ventricular internal dimensions and volume
• dilation of both heart chambers
• reactive fibrosis, interstitial
• analysis of cardiac output at P10 by measuring ejection fraction and fractional shortening reveals both are reduced by almost half in mutant mice when compared with those of control mice
• the percentage of proliferating cardiomyocyte cells (ratio of Ki-67-positive nuclei to total nuclei, multiplied by 100) is significantly increased in the mutant hearts compared with the control, which may contribute to the observed increase in heart mass
• mutant mice display at least a first-degree heart block at the atrioventricular node, with an 80% penetration of either nonsustained ventricular tachycardia, periodic third- degree heart block, or second-degree Type II heart block
• at P10, TUNEL staining reveals a dramatic increase in apoptotic cell death in mutant hearts compared with the control

cellular
• reactive fibrosis, interstitial
• the percentage of proliferating cardiomyocyte cells (ratio of Ki-67-positive nuclei to total nuclei, multiplied by 100) is significantly increased in the mutant hearts compared with the control, which may contribute to the observed increase in heart mass
• at P10, TUNEL staining reveals a dramatic increase in apoptotic cell death in mutant hearts compared with the control

muscle
• transmission electron microscopic (TEM) analysis reveals a significant increase of vacuoles in mutant myocytes, suggesting an increase in autophagic cell death
• the percentage of proliferating cardiomyocyte cells (ratio of Ki-67-positive nuclei to total nuclei, multiplied by 100) is significantly increased in the mutant hearts compared with the control, which may contribute to the observed increase in heart mass
• at P10, TUNEL staining reveals a dramatic increase in apoptotic cell death in mutant hearts compared with the control

growth/size/body
• heart to body weight ratios are increased compared with that of littermate controls; body weight is not significantly altered between controls and mutant mice

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
dilated cardiomyopathy 1A DOID:0110425 OMIM:115200
J:168140




Genotype
MGI:3042043
cn10
Allelic
Composition
Mapk7tm1Jdl/Mapk7tm1Jdl
Tg(Myhca-cre)1Abel/0
Genetic
Background
Not Specified
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mapk7tm1Jdl mutation (0 available); any Mapk7 mutation (32 available)
Tg(Myhca-cre)1Abel mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• mice were viable and showed no overt defects through 1 year of age





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/16/2024
MGI 6.23
The Jackson Laboratory